10
Main Session 1: MM A Novel Era of Promising Treatments for Patients with Multiple Myeloma Case Presentation Dr Carmen de Ramon Ortiz HUG, Geneva
Main Session 1: MM
A Novel Era of Promising Treatments for Patients with
Multiple MyelomaCase Presentation
Dr Carmen de Ramon OrtizHUG, Geneva
04.09.2020 2
• April 2010
• 70 yo male, good health: anemia (Hb 71g/l), fever
• Streptococcus agalactiae endocardites with mitral prolapse and mitral insufficiency (mitral plastia in juin 2010)
• Multiple Myeloma IgG kappa, Salmon and Durie IIA, ISS 2: • IgG kappa 74.30 g/l, IgA 0.33, IgM 0.18, FLC kappa 1010 mg/l, lambda 7.7.0, ratio 131.17• Normal renal fonction, Calcium LDH, B-2 microglogulin• Bone marrow infiltration: 60 % plasmocytes. Normal FISH.• X-ray series: lytique lesion at right femoral head and left humeral diaphisis
Case Presentation (M. C.)
04.09.2020 3
Treatment
0
10
20
30
40
50
60
70
80
M-protein evolution
IgG kappa
4xVCD
2xRD
VGPRVGPR VGPR
SD
auto8xRD
Rev
Pom-Dex
PD PDPD
What now?
04.09.2020 4
POLLUX
04.09.2020 5Dimopoulos et al, Nejm 2020
04.09.2020 6
04.09.2020 7
Updated POLLUX results
Bahlis et al, Leukemia 2020
04.09.2020 8
Treatment
0
10
20
30
40
50
60
70
80
M-protein evolution
IgG kappa
4xVCD
2xRD
VGPRVGPR VGPR
SD
auto8xRD
Rev
25xDara/Len/DexPom-Dex
VGPR
PD PDPD
04.09.2020 9
Take Home Message
• Multiple Myeloma is a chronic, incurable disease• Daratumumab is a monoclonal antibody
targeting CD38 present in plasma cells• Updated POLLUX results suggest long-term
responses• Daratumumab should be considered at least
after first relapse
